These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33115264)

  • 21. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
    Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
    Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
    Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
    Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer.
    Wu F; Zhang S; Xiong A; Gao G; Li W; Cai W; Su C; Chen X; Zhou F; Zhao J; Ren S; Zhou C
    Clin Lung Cancer; 2018 Nov; 19(6):e831-e842. PubMed ID: 30026059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
    Xu J; Liu X; Yang S; Shi Y
    Oncol Res; 2020 Mar; 28(2):127-133. PubMed ID: 31610827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy analysis of the radiotherapy and chemotherapy in patients with stage Ⅳ esophageal squamous carcinoma: a multicenter retrospective study of Jing-Jin-Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG R-01F)].
    Hu MM; Yuan QQ; Zhang XS; Yang S; Wang X; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Xu YG; Hao CL; Zhou ZG; Qie S; Lu N; Pang QS; Zhao YD; Sun XC; Li GF; Li L; Qiao XY; Liu ML; Wang YD; Li C; Zhu SC; Han C; Zhang KX; Xiao ZF
    Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):676-681. PubMed ID: 32867461
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
    Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
    Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment.
    Liao X; Li H; Liu Z; Liao S; Li Q; Liang C; Huang Y; Xie M; Wei J; Li Y
    Medicine (Baltimore); 2018 Dec; 97(50):e13635. PubMed ID: 30558053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma.
    Li J; Wang L
    Onco Targets Ther; 2017; 10():3965-3969. PubMed ID: 28860804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
    Duan JC; Wang ZJ; Lin L; Li JL; Wang Y; Bai H; Hu XS; Liu YT; Hao XZ; Wang HY; Wan R; Wang X; Wang J
    Invest New Drugs; 2019 Aug; 37(4):731-737. PubMed ID: 30706337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
    Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
    Liu L; Liu Y; Gong L; Zhang M; Wu W
    Cancer Biol Ther; 2020 Nov; 21(11):983-989. PubMed ID: 33092443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
    Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
    Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
    BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0): a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group].
    Lu N; Wang X; Li C; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Xiao ZF; Zhu SC; Han C; Qiao XY; Pang QS; Wang P; Zhao YD; Sun XC; Zhang KX; Li L; Li GF; Liu ML; Wang YD
    Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):139-144. PubMed ID: 32135649
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study.
    Li YH; Zhou Y; Wang YW; Tong L; Jiang RX; Xiao L; Zhang GJ; Xing SS; Qian F; Feng JQ; Zhao YL; Wang JG; Wang XH
    Medicine (Baltimore); 2018 Sep; 97(36):e12222. PubMed ID: 30200142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study.
    Xiao Y; Cheng H; Wang L; Yu X
    J Gynecol Oncol; 2020 Jan; 31(1):e2. PubMed ID: 31788992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.
    Zhang D; Zhang C; Huang J; Guan Y; Guo Q
    Thorac Cancer; 2018 Dec; 9(12):1754-1762. PubMed ID: 30338916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours.
    Liu G; Wang C; He Y; E M
    BMC Pharmacol Toxicol; 2019 Oct; 20(1):61. PubMed ID: 31661009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
    Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.